Cardiac involvement in Lysosomal Storage Diseases
| Autor: | Sestito, S., Parisi, F., Tallarico, V., Tarsitano, F., Roppa, K., Pensabene, L., Chimenz, R., GIORGIA CERAVOLO, Calabro, M. P., Sarro, R., Moricca, M. T., Bonapace, G., Concolino, D. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Lysosomal storage diseases (LSDs)
Heart Diseases Pompe disease (PD) valvular disease Heart Gaucher disease Anderson-Fabry disease (AFD) Mucopolysaccharidoses (MPSs) Lysosomal Storage Diseases Fabry Disease Humans Enzyme replacement therapy (ERT) Enzyme Replacement Therapy Anderson-Fabry disease (AFD) cardiomyopathy Enzyme replacement therapy (ERT) Gaucher disease Heart Lysosomal storage diseases (LSDs) Mucopolysaccharidoses (MPSs) Pompe disease (PD) valvular disease cardiomyopathy |
| Zdroj: | Scopus-Elsevier |
| Popis: | Lysosomal storage diseases (LSDs) include a heterogeneous group of rare, inborn, metabolic diseases characterized by deficiency of lysosomal enzymes or of other proteins involved in lysosomal function, leading to multi organ system substrates accumulation, with consequent multi systemic clinical presentation. Cardiac disease is particularly important in some group of LSDs as glycogen storage diseases (Pompe), mucopolysaccharidoses and in glycosphingolipidoses (Anderson-Fabry disease and less frequently Gaucher disease). Various cardiac manifestations may be observed including hypertrophic and dilated cardiomyopathy, coronary artery disease and valvular disease. The availability of enzyme replacement therapy (ERT) has changed the natural history of some LSDs such as Pompe disease, thanks to the significant effects on cardiological involvement. In other LSDs such as MPSs or Fabry disease, ERT has been shown to stabilize or slow the progression of heart damage. This imposes the need for a timely diagnosis that allows a rapid onset of ERT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|